Equities

KeyMed Biosciences Inc

KeyMed Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)44.70
  • Today's Change1.55 / 3.59%
  • Shares traded1.53m
  • 1 Year change-25.81%
  • Beta0.6206
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy4
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The 7 analysts offering 12 month price targets for Keymed Biosciences Inc have a median target of 58.74, with a high estimate of 71.99 and a low estimate of 49.99. The median estimate represents a 31.41% increase from the last price of 44.70.
High61.0%71.99
Med31.4%58.74
Low11.8%49.99

Earnings history & estimates in CNY

Keymed Biosciences Inc reported annual 2023 losses of -1.37 per share on Mar 26, 2024.
Average growth rate+39.51%
More ▼

Revenue history & estimates in CNY

Keymed Biosciences Inc had revenues for the full year 2023 of 354.10m. This was 253.87% above the prior year's results.
Average growth rate+122.31%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.